Carbonic anhydrase IX as a target for metastatic disease

Roben Gieling, Kaye J. Williams

Research output: Contribution to journalArticlepeer-review

48 Citations (Scopus)


Metastatic disease is responsible for the majority of cancer related deaths. Tumour-associated carbonic anhydrase IX (CA IX) is a powerful marker to diagnose various types of metastatic cancers including those of cervical, renal, breast and head & neck origin. The precise prognostic role of CA IX in determining local control versus overall survival is complex, although the majority of reports favour CA IX as a marker for poor prognosis in patients with metastatic cancer. Preclinical studies in cell cultures clearly demonstrate that CA IX stimulates features that enhance metastatic properties of cancer cells for example, reducing cell adhesion, increasing motility and migration, inducing vascularisation and activating proteases, in which CA IX-induced acidification of the microenvironment of the tumour is essential. As most findings are consistent with the idea that CA IX is important in metastatic dissemination, small molecular CA IX inhibitors (including fluorescent-tagged or radiolabelled) and monoclonal antibodies targeting the CA IX isoform have been developed. Studies in tumour xenograft models showed that these CA IX-specific inhibitors and antibodies can be very effective in therapy and imaging of a variety of different metastatic cancers.
Original languageEnglish
Pages (from-to)1470-1476
Number of pages7
JournalBioorganic and Medicinal Chemistry
Issue number6
Early online date11 Oct 2012
Publication statusPublished - 15 Mar 2013


Dive into the research topics of 'Carbonic anhydrase IX as a target for metastatic disease'. Together they form a unique fingerprint.

Cite this